- Tiaprofenic acid
-
- $10.00 / 1KG
-
2026-01-05
- CAS:33005-95-7
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 10 mt
- Tiaprofenic acid
-
- $34.00 / 10mg
-
2026-01-04
- CAS:33005-95-7
- Min. Order:
- Purity: 99.69%
- Supply Ability: 10g
- Tiaprofenic acid
-
- $667.00 / 1KG
-
2025-12-03
- CAS:33005-95-7
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 100kg
|
| | Tiaprofenic acid Basic information |
| Product Name: | Tiaprofenic acid | | Synonyms: | TIAPROFENIC ACID EPT(CRM STANDARD);Tiaprofenic;(RS)-Tiaprofenic acid;2-Thiopheneacetic acid, 5-benzoyl-a-methyl- (8CI, 9CI);FC 3001;RU 15060;Suralgan;Surgam | | CAS: | 33005-95-7 | | MF: | C14H12O3S | | MW: | 260.31 | | EINECS: | 251-329-3 | | Product Categories: | | | Mol File: | 33005-95-7.mol |  |
| | Tiaprofenic acid Chemical Properties |
| Melting point | 96° (isopropyl ether) | | Boiling point | 373.57°C (rough estimate) | | density | 1.2959 (rough estimate) | | refractive index | 1.5050 (estimate) | | storage temp. | 2-8°C(protect from light) | | solubility | Practically insoluble in water, freely soluble in acetone, in ethanol (96 per cent) and in methylene chloride. | | pka | 4.05±0.10(Predicted) | | form | Solid | | color | White to Almost white | | λmax | 314nm(Phosphate buffer sol.)(lit.) | | Merck | 14,9422 | | Major Application | pharmaceutical (small molecule) | | InChI | InChI=1S/C14H12O3S/c1-9(14(16)17)11-7-8-12(18-11)13(15)10-5-3-2-4-6-10/h2-9H,1H3,(H,16,17) | | InChIKey | GUHPRPJDBZHYCJ-UHFFFAOYSA-N | | SMILES | C1(=CC=C(C(C)C(=O)O)S1)C(=O)C1C=CC=CC=1 |
| RIDADR | UN 2811 6.1/PG III | | WGK Germany | WGK 3 | | RTECS | XM7580000 | | HS Code | 2934.99.3000 | | HazardClass | 6.1 | | PackingGroup | III | | Storage Class | 6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects | | Hazard Classifications | Acute Tox. 3 Oral
Repr. 2 |
| | Tiaprofenic acid Usage And Synthesis |
| Chemical Properties | White or almost white, crystalline powder. | | Originator | Surgam,Roussel,France,1975 | | Uses | Antiinflammatory;Cyclooxygenase inhibitor | | Definition | ChEBI: An aromatic ketone that is thiophene substituted at C-2 by benzoyl and at C-4 by a 1-carboxyethyl group. | | Manufacturing Process | A mixture of 10.3 g of thiophene-2α-methylacetic acid [prepared by process of
Bercot-Vatteroni, et al., Bull. Soc. Chim. (1961) pp. 1820-21], 11.10 g of
benzoyl chloride and a suspension of 23.73 g of aluminum chloride in 110 cc
of chloroform was allowed to stand for 15 minutes and was then poured into a
mixture of ice and hydrochloric acid. The chloroform phase was extracted with
a 10% aqueous potassium carbonate solution and the aqueous alkaline phase
was acidified with N hydrochloric acid and was then extracted with ether. The
ether was evaporated off and the residue was crystallized from carbon
tetrachloride to obtain a 54% yield of 5-benzoyl-thiophene-2α-methylacetic
acid melting at 83°C to 85°C. The product occurred in the form of colorless
crystals soluble in dilute alkaline solutions, alcohol and ether and insoluble in
water. | | Therapeutic Function | Antiinflammatory | | Drug interactions | Potentially hazardous interactions with other drugs
ACE inhibitors and angiotensin-II antagonists:
antagonism of hypotensive effect; increased risk of
nephrotoxicity and hyperkalaemia.
Analgesics: avoid concomitant use of 2 or more
NSAIDs, including aspirin (increased side effects);
avoid with ketorolac (increased risk of side effects
and haemorrhage).
Antibacterials: possibly increased risk of convulsions
with quinolones.
Anticoagulants: effects of coumarins and
phenindione enhanced; possibly increased risk of
bleeding with heparins, dabigatran and edoxaban -
avoid long term use with edoxaban.
Antidepressants: increased risk of bleeding with
SSRIs and venlaflaxine.
Antidiabetic agents: effects of sulphonylureas
enhanced.
Antiepileptics: possibly increased phenytoin
concentration.
Antivirals: increased risk of haematological toxicity
with zidovudine; concentration increased by
ritonavir.
Ciclosporin: may potentiate nephrotoxicity.
Cytotoxics: reduced excretion of methotrexate;
increased risk of bleeding with erlotinib.
Diuretics: increased risk of nephrotoxicity;
antagonism of diuretic effect; hyperkalaemia with
potassium-sparing diuretics.
Lithium: excretion decreased.
Pentoxifylline: increased risk of bleeding.
Tacrolimus: increased risk of nephrotoxicity. | | Metabolism | Sparingly metabolised in the liver to two inactive metabolites. Excretion of tiaprofenic acid and its metabolites are mainly in the urine in the form of acyl glucuronides; some is excreted in the bile. |
| | Tiaprofenic acid Preparation Products And Raw materials |
|